101 results
Page 3 of 6
8-K
EX-99.1
uoikx9xnev
10 Dec 21
Regulation FD Disclosure
8:16am
8-K
EX-99.1
z8q r3c5g2dv
3 Nov 21
Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update
4:01pm
8-K
EX-99.1
04e29d3n8w17wxes785m
28 Sep 21
Regulation FD Disclosure
7:30am
424B5
cjds7tzv5
6 Aug 21
Prospectus supplement for primary offering
4:34pm
8-K
EX-1.1
t49o049
6 Aug 21
Entry into a Material Definitive Agreement
4:09pm
8-K
EX-10.1
rwhx t9e1znbi55y0
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTACĀ® Protein
7:30am
8-K
EX-99.1
d763w7wo
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTACĀ® Protein
7:30am
8-K
EX-99.1
xd9vwmefr6vz64uad
4 May 21
Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:02pm
8-K
EX-99.1
tzxd kzrn2l
1 Mar 21
Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-1.1
012hs59udj35tkt
18 Dec 20
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
6:30am
424B5
1mgxa8h886zb2or20
16 Dec 20
Prospectus supplement for primary offering
4:01pm
424B5
y5zwla5
14 Dec 20
Prospectus supplement for primary offering
4:48pm
8-K
EX-99.2
y3cxza5vt vfpa1yh0
14 Dec 20
Regulation FD Disclosure
7:30am
8-K
oleasw6pxne4j v0a4
14 Dec 20
Regulation FD Disclosure
7:30am